GRN

AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia

Retrieved on: 
Tuesday, May 17, 2022
LifeArc, NEA, FTD, Serum, Dementia, Death, Capital, Autosome, Gene, Pathology, GRN, Patient, Language, Neurology, Liver, Society, Amyotrophic lateral sclerosis, EST, Neurodegeneration, Frontotemporal dementia, Research, CNS, Brain, AAV, Central nervous system, HIV disease progression rates, DDF, New Enterprise Associates, LinkedIn, Twitter, Cell, Diagnosis, ALS, CEO, Vaccine, Pharmaceutical industry

The data being presented are from pre-clinical studies with AVB-101 to treat frontotemporal dementia with GRN mutations (FTD-GRN).

Key Points: 
  • The data being presented are from pre-clinical studies with AVB-101 to treat frontotemporal dementia with GRN mutations (FTD-GRN).
  • The findings from the biodistribution studies are particularly exciting, demonstrating that effective and targeted distribution of a gene therapy is possible via intrathalamic injection.
  • AviadoBios unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery.
  • Frontotemporal dementia (FTD) is of the second most common form of dementia in people under the age of 65 after Alzheimers disease.

AviadoBio Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, May 12, 2022
Neurosurgery, LifeArc, NEA, Dementia, Capital, Ludwig Cancer Research, Ohio State University College of Medicine, Molecular medicine, Radiology, University of California, University, Neuroscientist, Twitter, SAB, FTD, Master of Science, Autosome, Gene, Neurodegeneration, Research, Brain, Board, UMMS, Frontotemporal dementia, Harvard Medical School, Department, Death, Doctor of Philosophy, Language, Amyotrophic lateral sclerosis, University college, Central nervous system, LinkedIn, Massachusetts General Hospital, Coronavirus Scientific Advisory Board (Turkey), ALS, Assistant, GRN, Patient, AAV, WWE Performance Center, DDF, New Enterprise Associates, Journal of Cellular and Molecular Medicine, Diagnosis, CEO, Pharmaceutical industry, Vaccine, Management, MD, Neurology, Neuroscience

Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and neurological gene therapy

Key Points: 
  • Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and neurological gene therapy
    London, UK, May 12, 2022 AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) comprising world-leading experts in neurodegenerative diseases, neurosurgical drug delivery and gene therapy development.
  • Lisa Deschamps, CEO of AviadoBio, said: "Attracting such an esteemed and diverse group of neurodegenerative disease, neurosurgery and gene therapy experts to the AviadoBio team is a testament to the strength of our differentiated approach.
  • Professor Chris Shaw, commented: I am delighted to Chair AviadoBios Scientific Advisory Board, which includes world-leading experts in their respective fields.
  • For more information, please visit www.aviadobio.com and follow us at Twitter @AviadoBio and LinkedIn AviadoBio.

AviadoBio Announces Formation of Scientific Advisory Board  

Retrieved on: 
Thursday, May 12, 2022
Neurosurgery, LifeArc, NEA, Dementia, Capital, Ludwig Cancer Research, Ohio State University College of Medicine, Molecular medicine, Radiology, University of California, University, Neuroscientist, Twitter, SAB, FTD, Master of Science, Autosome, Gene, Neurodegeneration, Research, Brain, Board, UMMS, Frontotemporal dementia, Harvard Medical School, Department, Death, Doctor of Philosophy, Language, Amyotrophic lateral sclerosis, University college, Central nervous system, LinkedIn, Massachusetts General Hospital, Coronavirus Scientific Advisory Board (Turkey), ALS, Assistant, GRN, Patient, AAV, WWE Performance Center, DDF, New Enterprise Associates, Journal of Cellular and Molecular Medicine, Diagnosis, CEO, Pharmaceutical industry, Vaccine, Management, MD, Neurology, Neuroscience

Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and neurological gene therapy

Key Points: 
  • Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and neurological gene therapy
    London, UK, May 12, 2022 AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) comprising world-leading experts in neurodegenerative diseases, neurosurgical drug delivery and gene therapy development.
  • Lisa Deschamps, CEO of AviadoBio, said: "Attracting such an esteemed and diverse group of neurodegenerative disease, neurosurgery and gene therapy experts to the AviadoBio team is a testament to the strength of our differentiated approach.
  • Professor Chris Shaw, commented: I am delighted to Chair AviadoBios Scientific Advisory Board, which includes world-leading experts in their respective fields.
  • For more information, please visit www.aviadobio.com and follow us at Twitter @AviadoBio and LinkedIn AviadoBio.

Bergen New Bridge Medical Center Signs with Guardian Research Network® to Help Change How Healthcare is Delivered and Provide Added Diversity to Data Science and Innovation

Retrieved on: 
Tuesday, May 10, 2022
GRN, COVID 19, Ambulatory care, New Jersey Medical School, Medical Center, Joint Commission, Adventist HealthCare White Oak Medical Center, Safety, Physician, Translation, Patient, COVID, Degenerative disease, Cancer, Diabetes, Toronto Seniors Services and Long-Term Care Division, Therapy, HRC, Veteran, Health, Disease, HEI, Long-term care, Mental health, Human Rights Campaign, CEO, Technology, Research, Pharmacy, Hospital, Pharmaceutical industry, Rutgers University

SPARTANBURG, S.C., May 10, 2022 /PRNewswire/ -- Guardian Research Network Inc. (GRN) announced today that Bergen New Bridge Medical Center, New Jersey's largest hospital and a clinical affiliate of Rutgers University Medical School, has joined its nationwide healthcare system research network. As not-for-profits, both entities come together to bring healthcare innovation to local communities and enhance patient diversity in a focus on improved healthcare.

Key Points: 
  • As not-for-profits, both entities come together to bring healthcare innovation to local communities and enhance patient diversity in a focus on improved healthcare.
  • The strategic relationship will contribute to GRN's mission of translating data into cures and providing research answers for improved health.
  • Bergen New Bridge will be embarking on cutting-edge diagnostic studies in communities that do not traditionally seek healthcare early.
  • Representing millions of patients across the country, GRN focuses on advancing healthcare data technology, clinical research trials, and real-world data science.

AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022

Retrieved on: 
Wednesday, May 4, 2022
Gene, Amyotrophic lateral sclerosis, GRN, LifeArc, FTD, Brain, Twitter, Q&A, Frontotemporal dementia, Death, Cell, AAV, EST, Patient, Autosome, DDF, Pathology, Diagnosis, Capital, New Enterprise Associates, Neurology, Dementia, LinkedIn, Society, Language, NEA, Research, ALS, Central nervous system, Neurodegeneration, Pharmaceutical industry

The data are from studies it has conducted with its investigational, one-time, adeno-associated virus (AAV) gene therapy, AVB-101 (AVB-PGRN), for the treatment of frontotemporal dementia with GRN mutations (FTD-GRN).

Key Points: 
  • The data are from studies it has conducted with its investigational, one-time, adeno-associated virus (AAV) gene therapy, AVB-101 (AVB-PGRN), for the treatment of frontotemporal dementia with GRN mutations (FTD-GRN).
  • The presentation will form part of the session Applications of Improved Gene Therapy Methods in Neurologic Disorders and will be followed by a Q&A discussion.
  • AviadoBios unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery.
  • Frontotemporal dementia (FTD) is of the second most common form of dementia in people under the age of 65 after Alzheimers disease.

AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy

Retrieved on: 
Monday, May 2, 2022
ACHM, COVID-19, Drug development, GRN, Forward-looking statement, Capsid, FTD, Mutation, Nasdaq, Stargardt disease, B cell, GLOBE, CNS, HEK 293 cells, Applied Genetic Technologies Corporation, Cell, Cerebrospinal fluid, AAV, ICM, Retina, Annual report, Poster, Central nervous system disease, Patient, A4, Achromatopsia, ATP, Gene, Neurodegeneration, FDT, Risk, Therapy, Frontotemporal dementia, Gene expression, Form 10-K, Primate, Neurotology, Dementia, Optogenetics, Society, Disease, SEC, ABCA4, Technology, Research, Central nervous system, Vaccine, Antibiotics, Granulin, D.C

We believe the preclinical findings in frontotemporal dementia are particularly encouraging and look forward to continuing our research to support a potential future Investigational New Drug Application filing.

Key Points: 
  • We believe the preclinical findings in frontotemporal dementia are particularly encouraging and look forward to continuing our research to support a potential future Investigational New Drug Application filing.
  • Results support the feasibility of augmenting progranulin expression via AAV-GRN gene therapy as a potential treatment for FDT caused by GRN mutations.
  • AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases.
  • Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release.

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

Retrieved on: 
Wednesday, April 27, 2022
Patient, ALS, Frontotemporal dementia, CEO, FTD, European Commission, Twitter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Capital, DDF, Food, EC, Autosome, New Enterprise Associates, Central nervous system, Dementia, Personality, LinkedIn, GRN, Friends, Amyotrophic lateral sclerosis, Royal commission, AAV, Even and odd functions, Language, Apathy, Gene, NEA, LifeArc, Granulin, FDA, Disease, Neurodegeneration, Time, Pharmaceutical industry, EU

AVB-101 is an investigational, adeno-associated virus (AAV) gene therapy designed for FTD patients with mutations in the Progranulin (GRN) gene.

Key Points: 
  • AVB-101 is an investigational, adeno-associated virus (AAV) gene therapy designed for FTD patients with mutations in the Progranulin (GRN) gene.
  • AviadoBios unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery.
  • Frontotemporal dementia (FTD) is one of most common forms of dementia in individuals under the age of 65 (second after Alzheimers disease).
  • AviadoBios AVB-101 is an investigational, one-time, adeno-associated virus (AAV) gene therapy for patients with Frontotemporal Dementia (FTD) with mutations in the GRN gene.

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

Retrieved on: 
Wednesday, April 27, 2022
Patient, ALS, Frontotemporal dementia, CEO, FTD, European Commission, Twitter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Capital, DDF, Food, EC, Autosome, New Enterprise Associates, Central nervous system, Dementia, Personality, LinkedIn, GRN, Friends, Amyotrophic lateral sclerosis, Royal commission, AAV, Even and odd functions, Language, Apathy, Gene, NEA, LifeArc, Granulin, FDA, Disease, Neurodegeneration, Time, Pharmaceutical industry, EU

AVB-101 is an investigational, adeno-associated virus (AAV) gene therapy designed for FTD patients with mutations in the Progranulin (GRN) gene.

Key Points: 
  • AVB-101 is an investigational, adeno-associated virus (AAV) gene therapy designed for FTD patients with mutations in the Progranulin (GRN) gene.
  • AviadoBios unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery.
  • Frontotemporal dementia (FTD) is one of most common forms of dementia in individuals under the age of 65 (second after Alzheimers disease).
  • AviadoBios AVB-101 is an investigational, one-time, adeno-associated virus (AAV) gene therapy for patients with Frontotemporal Dementia (FTD) with mutations in the GRN gene.

Guardian Research Network and Cytel Announce Presentation at ISPOR 2022 Detailing Covid-19's Impact on Breast Cancer

Retrieved on: 
Wednesday, April 27, 2022
COVID-19, Adult, Operational Research CONsultancy, Research, Diagnosis, Patient, GRN, Breast, Technology, Breast cancer, Solution, TNM, Physician, Hurmiz Malik Chikko, Interim, Cancer, Pharmaceutical industry, Medical imaging, Medical device, Cytel, Guardian

SPARTANBURG, S.C., April 27, 2022 /PRNewswire/ -- Guardian Research Network, Inc. (GRN) and Cytel Inc. are pleased to announce an upcoming presentation at ISPOR 2022, Washington, DC. ISPOR is the leading professional society for health economics and outcomes research. The session, titled "Studies on COVID-19 Healthcare Impacts" will detail multiple studies, including "Evaluating the impact of COVID-19 on the diagnosis and staging of new breast cancer cases: A retrospective analysis of medical chart data from the United States," scheduled for 10 a.m. ET, Wednesday, May 18, 2022.

Key Points: 
  • SPARTANBURG,S.C., April 27, 2022 /PRNewswire/ -- Guardian Research Network, Inc. (GRN) and Cytel Inc. are pleased to announce an upcoming presentation at ISPOR 2022, Washington, DC.
  • To be delivered by Rachel Knapp, Research Consultant, Cytel Inc., the specific study is a retrospective analysis of electronic medical record data provided by GRN.
  • "We are pleased to work with Cytel to use GRN's millions of real-world cancer records to translate Covid-19 data into insights on the treatment of breast cancer.
  • Guardian Research Network, a non-profit organization, is a nationwide health system consortium focused on advancing technology to accelerate cures for life-threatening diseases such as cancer.

Fidelis New Energy Expands its Clean Energy Logistics, Feedstock & Commercial Capabilities

Retrieved on: 
Thursday, March 24, 2022
Quanta, SAF, COO, Board, GRN, JBS, Phillips, Baton Rouge metropolitan area, Ecosystem, CEO, Business action on climate change, Specialization, Carbon, Phillips 66, Entrepreneurship, Hydrocarbon, LLC, Board of directors, Industry, Time, The Shaw Group, Partner, Port, Engineering, Port of Greater Baton Rouge, Aviation biofuel, Fidelis, Neste, Renewable energy

HOUSTON, March 24, 2022 /PRNewswire/ -- Fidelis New Energy, LLC ("Fidelis"), a leading developer, investor, and operator of climate impact infrastructure, announced the addition of three industry veterans to lead its logistics, feedstock procurement, trading, and origination activities through the appointment of Greg Smith as SVP Commercial & Logistics, John Reynolds as VP Commercial & Supply, and Claire Foster as Lead Originator.

Key Points: 
  • "We are pleased to welcome Greg, John and Claire to the team to continue to execute on our strategy of securing strategic renewable feedstock relationships, partnerships and agreements," said Dan Shapiro, CEO and Co-Founder, Fidelis.
  • In combination these components are designed to enable the production of carbon negative fuels and materials, utilizing only proven technologies.
  • Greg Smith added, "The Grn Fuels integrated ecosystem, logistical advantages, and flexible pretreatment support a negative carbon intensity score, positioning Fidelis for long-term success."
  • Greg leads the comprehensive supply, trading and logistics organization that actionably pursues advantaged feedstock strategies, procurement, and logistics development.